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Abstract 
Background 
The accurate clinical characterisation of mild cognitive impairment (MCI) is becoming increasingly 
important. The aim of this study was to compare the neuropsychiatric symptoms and cognitive 
profile of MCI with Lewy bodies (MCI-LB) with Alzheimer’s disease MCI (MCI-AD). 
 
Methods 
Participants were ≥60 years old with MCI. Each had a thorough clinical and neuropsychological 
assessment and FP-CIT SPECT.  MCI-LB was diagnosed if two or more diagnostic features of DLB were 
present (visual hallucinations, cognitive fluctuations, motor parkinsonism, REM sleep behaviour 
disorder or positive FP-CIT SPECT). A Lewy body Neuropsychiatric Supportive Symptom Count 
(LBNSSC) was calculated based on the presence or absence of the supportive neuropsychiatric 
symptoms defined by the 2017 dementia with Lewy bodies (DLB) diagnostic criteria: non-visual 
hallucinations, delusions, anxiety, depression and apathy. 
 
Results 
MCI-LB (n=41) had a higher LBNSSC than MCI-AD (n=24; 1.8±1.1 v 0.7±0.9, p=0.001). 67% of MCI-LB 
had two or more of those symptoms, compared with 16% of MCI-AD (Likelihood ratio=4.2, p<0.001). 
MCI-LB subjects scored lower on tests of attention, visuospatial function and verbal fluency. 
However, cognitive test scores alone did not accurately differentiate MCI-LB from MCI-AD. 
 
Conclusions 
MCI-LB is associated with neuropsychiatric symptoms and a cognitive profile similar to established 
DLB. This supports the concept of identifying MCI-LB based on the presence of core diagnostic 
features of DLB and abnormal FP-CIT SPECT imaging. The presence of supportive neuropsychiatric 
clinical features identified in the 2017 DLB diagnostic criteria was helpful in differentiating between 
MCI-LB and MCI-AD.  
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Background 
The accurate clinical characterisation of mild cognitive impairment (MCI) is becoming increasingly 
important as treatment studies move into the prodromal stages of disease and patients present 
earlier in the disease process when seeking a diagnosis. Dementia with Lewy bodies (DLB) is the 
second most common type of neurodegenerative dementia, accounting for 7.5% of cases in 
secondary care (Vann Jones and O'Brien, 2014). Despite this, there is a relative paucity of research 
into the clinical and neuropsychological presentation of the MCI phase of DLB (MCI-LB). The recently 
revised Diagnostic Criteria for DLB (McKeith et al., 2017) list four core diagnostic features for the 
disease - visual hallucinations, motor parkinsonism, cognitive fluctuations and clinical REM sleep 
behaviour disorder (RBD). In addition, the consensus paper also lists supportive clinical features, 
which are less specific than the core features but are thought to be potentially indicative of DLB, 
particularly where they are persistent or appear in combination.  There are five neuropsychiatric 
symptoms in the supportive clinical features: hallucinations in non-visual modalities, systematised 
delusions, apathy, anxiety and depression. There is evidence suggesting the presence of core 
features of DLB in the prodromal phase of disease (Donaghy et al., 2015). However there has been 
little investigation of other neuropsychiatric symptoms in prodromal DLB. 
 
In addition to specific neuropsychiatric symptoms, DLB is also associated with a characteristic 
pattern of cognitive impairment. Compared with Alzheimer’s disease (AD), DLB is associated with 
greater impairment in attention, executive and visuospatial function, but less severe memory 
impairment (Metzler-Baddeley, 2007). It has been shown that people with non-amnestic MCI are 
much more likely to convert to DLB than AD, whereas the reverse is true for amnestic MCI (Ferman 
et al., 2013). Visuospatial dysfunction was found at the first clinical presentation of the majority of 
patients with a post-mortem diagnosis of DLB (Tiraboschi et al., 2006).  There is emerging evidence 
that the characteristic Lewy body profile of attention, executive and visuospatial dysfunction is 
already present at the MCI phase of DLB (Cagnin et al., 2015, Yoon et al., 2015, Kemp et al., 2017, 
Sadiq et al., 2017). 
 
Aims and Hypotheses 
The aim of this study was to compare the neuropsychiatric symptoms and cognitive profile of MCI-LB 
with MCI-AD. 
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The hypothesis was that MCI-LB would display a neuropsychiatric and cognitive profile similar to that 
seen in DLB with higher rates of non-visual hallucinations, depression, apathy, anxiety and delusions 
and deficits in attention, executive and visuospatial function, with relatively preserved memory 
function when compared to MCI-AD. 
 
Methods 
Participants 
MCI subjects ≥60 years old were recruited from memory clinics, elderly medicine clinics and 
neurology clinics in the North East of England and Cumbria. Potential study subjects were eligible for 
participation if they were reported to have at least one clinical symptom that may be associated 
with DLB. Such symptoms included autonomic symptoms, visual disturbances, olfactory impairment 
and mood changes as well as any indication of the presence of core and supportive features of DLB. 
Subjects were excluded if they had dementia, an MMSE score <20, a CDR score of >0.5, parkinsonism 
that developed more than one year prior to cognitive impairment or evidence of clinical stroke or a 
serious neurological or medical condition that would affect their performance in study assessments. 
All subjects gave their written informed consent to take part in the study. The study received ethical 
approval from the National Research Ethics Service Committee North East - Newcastle & North 
Tyneside 2 (Research Ethics Committee Identification Number 12/NE/0290). 
 
Neuropsychological Assessment 
Subjects had a thorough neuropsychological assessment including the Addenbrooke’s Cognitive 
Examination Revised (ACE-R) (Mioshi et al., 2006), FAS Verbal Fluency (Borkowski et al., 1966), the 
Trail-making Test Parts A and B (Reitan, 1955), the Graded Naming Test (GNT) (McKenna and 
Warrington, 2007) and the Rey Auditory Verbal Learning Test (AVLT) (Rey, 1964). Computerised tests 
of simple and choice reaction time and digit vigilance (Ballard et al., 2001) were used to measure 
attention and executive function. Variation in reaction time was measured using the coefficient of 
variation (standard deviation of reaction time/mean reaction time). Cognitive processing time was 
calculated as the difference between the choice and simple reaction times. 
Computerised tasks measuring line angle discrimination (Wood et al., 2013) and motion detection 
were used to measure visuospatial function. The motion detection task was based on that reported 
by Salmon and colleagues (Landy et al., 2015). Briefly, moving white dots were presented on the 
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computer screen for 1 second. A proportion of the dots were either moving horizontally to the right 
or to the left (signal). The rest of the dots were moving randomly (noise). The participant had to 
decide if the signal dots were moving to the right or the left. The program modified difficulty based 
on the participant’s responses; the output was a threshold of the proportion of signal dots that the 
participant required to correctly identify the direction of movement. 
 
Clinical Assessment 
All patients were assessed by the equivalent of a Board Certified Psychiatrist (PCD), who carried out 
a physical and neurological examination. Blood pressure was measured lying and after standing for 
three minutes. Where one was available, a relative, friend or carer was also interviewed. 
Quantitative scales were used to assess neuropsychiatric symptoms (Geriatric Depression Scale 
(D'Ath, et al. 1994), Clinician Assessment of Fluctuations (Walker, et al. 2000), Dementia Cognitive 
Fluctuations Scale (DCFS) (Lee, et al. 2014), Neuropsychiatric Inventory (NPI) (Cummings, et al. 
1994), Mayo Sleep Questionnaire (Boeve et al., 2011)), parkinsonism (Revised Unified Parkinson’s 
disease Rating Scale Motor Sub-scale (Goetz, et al. 2008)) and level of functional impairment 
(Instrumental Activities of Daily Living Scale (Lawton and Brody 1969)). Further clinical and 
neuropsychological assessments have been carried out annually and data from the first annual 
review was used to review the participant’s diagnosis.  
 
The presence or absence of neuropsychiatric symptoms listed as ‘supportive clinical features’ in the 
2017 DLB Criteria (McKeith et al., 2017) was determined from the relevant section of the 
Neuropsychiatric Inventory: delusions (Section A); non-visual hallucinations (Section B1/B4/B5/B6); 
depression (Section D), anxiety (Section E) and apathy (Section G). An affirmative response in the 
relevant section indicated the presence of the symptom. The Lewy Body Neuropsychiatric 
Supportive Symptom Count (LBNSSC) was defined as the total number of symptoms experienced by 
each patient (maximum=5).   
 
FP-CIT SPECT 
FP-CIT SPECT imaging was carried out at baseline. Three to six hours following a bolus intravenous 
injection of 185 MBq of 123I-FP-CIT (DaTSCAN, GE Healthcare, UK) patients were scanned using a 
double headed gamma camera (Siemens Symbia S) fitted with a low energy high resolution (LEHR) 
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parallel hole collimator. Images were reconstructed in transverse sections and classed as normal or 
abnormal based on visual rating (Benamer et al., 2000). 
 
Diagnosis 
An expert consensus clinical panel (AJT, PCD, JPT) reviewed all the clinical assessment data to 
confirm subjects met NIA-AA MCI criteria (Albert et al., 2011) without considering aetiology. Where 
the first two raters did not agree, the third made a final decision. The consensus panel also rated the 
presence or absence of each of the four core symptoms of DLB (cognitive fluctuations, complex 
visual hallucinations, clinical parkinsonism and clinical RBD). This was performed blind to FP-CIT 
SPECT result. These ratings and the FP-CIT SPECT result were used to classify participants as Probable 
MCI-LB (NIA-AA MCI plus two or more of the five diagnostic features (four core symptoms and 
abnormal FP-CIT SPECT)) or MCI-AD (MCI with none of the four core symptoms, evidence of decline 
which was characteristic of AD with no evidence for another aetiology and a normal FP-CIT scan). 
The ‘one year rule’ was applied so that no subjects had had evidence of Parkinsonism for more than 
a year before the onset of their cognitive decline. Assignment to these diagnostic categories was 
based on information from both baseline and one year follow-up clinical evaluations.  
 
The Mayo Sleep Questionnaire was completed where an informant that lived with the participant 
was present, as stipulated in the questionnaire. However, the classification of the presence or 
absence of RBD also incorporated other information e.g. where a subject or informant could reliably 
relay the report of a bed-partner, or the outcome of assessment at a sleep clinic.  
 
Statistics 
Demographic and clinical data was compared using t-tests, Mann-Whitney U tests, Chi-squared and 
Fisher’s Exact tests depending on the nature of the data. Cognitive performance in the MCI-LB and 
MCI-AD groups was compared using the general linear model and logistic regression with age, 
gender and years in education as covariates. 
 
Results  
77 subjects completed their baseline assessment, of which 41 were classified as MCI-LB and 24 as 
MCI-AD. 12 subjects had one core symptom or a positive FP-CIT SPECT scan. These subjects were 
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considered to have possible MCI-LB. Due to the uncertainty regarding the aetiology of their cognitive 
impairment they were excluded from further analysis. Hereafter MCI-LB refers exclusively to 
probable MCI-LB. The MCI-LB group were more likely to be male (Table 1). The most common 
diagnostic feature in the MCI-LB group at baseline was an abnormal FP-CIT scan (67%) followed by 
cognitive fluctuations (56%), RBD (49%), parkinsonism (46%) and visual hallucinations (29%, Figure 
2). No participants reported a history of neuroleptic sensitivity. 
 
Figure 1 Here 
Figure 2 Here 
Table 1 Here 
 
As expected, MCI-LB subjects had higher scores in scales measuring diagnostic features such as 
parkinsonism, visual hallucinations and fluctuations in cognition and arousal. They also had greater 
depressive symptoms measured by the GDS, more severe neuropsychiatric symptoms and greater 
carer distress measured by the NPI. The NPI domains that were significantly more commonly 
reported by the carers of people with MCI-LB were anxiety (46% v 11%; p=0.01), apathy/indifference 
(54% v 21%; p=0.02) and sleep (59% v 26%, p=0.02; Table 2).  
 
The LBNSSC was greater in MCI-LB than MCI-AD (1.8±1.1 v 0.7±0.9, p=0.001). 67% of MCI-LB had two 
or more of these symptoms, compared with 16% of MCI-AD (Likelihood ratio=4.2, p<0.001). 23% of 
MCI-LB cases had three or more of these symptoms compared with 5% of MCI-AD (Likelihood 
Ratio=4.4, p=0.07).  
 
Table 2 Here 
 
The MCI-LB group had relatively lower blood pressure on standing compared to the MCI-AD group. 
However, postural hypotension (defined as a 20mmHg or greater drop in systolic BP) was not 
common in either group (MCI-LB 21% v 9% MCI-AD; p=0.31). 
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The results of cognitive tests are shown in Table 3. The overall degree of cognitive impairment was 
similar in both groups. Compared with MCI-AD subjects, MCI-LB was associated with poorer 
performance on verbal fluency (both letter and animal) on the ACE-R and a trend towards a similar 
finding in the FAS. Their reaction times were also slower on the digit vigilance task. There were 
statistical trends toward a lower number of items correctly identified on the digit vigilance task and 
slower cognitive processing (p<0.10). MCI-LB participants had worse visuospatial function measured 
by the ACE-R and the angle discrimination task compared to MCI-AD. There were no differences 
between the groups on ACE-R memory, Rey delayed recall or Rey recognition. 37% of MCI-LB were 
>2 SD below the age adjusted mean for delayed recall. 
 
Table 3 Here 
 
Using the four cognitive tests that demonstrated statistically significantly differences (ACE-R fluency 
and visuospatial, digit vigilance time and angle task result) in a post-hoc discriminant analysis yielded 
a sensitivity of 64% and specificity of 68% for the identification of MCI-LB, with an overall accuracy of 
66%.  
 
Discussion 
The recently revised consensus criteria for the diagnosis of DLB (McKeith et al., 2017) list a range of 
supportive clinical features in addition to the core diagnostic clinical features of visual hallucinations, 
spontaneous motor parkinsonism, cognitive fluctuations and clinical RBD. The supportive clinical 
features include five neuropsychiatric symptoms: non-visual hallucinations, delusions, anxiety, 
depression and apathy. Consistent with our hypothesis, MCI-LB subjects were significantly more 
likely to have two or more of these symptoms than MCI-AD subjects, with a likelihood ratio of 4.2. 
This means that subjects with MCI-LB are more than four times more likely to have two or more of 
these symptoms than subjects with MCI-AD. Whilst our finding requires replication, these 
symptoms, identified as supportive in the diagnostic criteria, do indeed appear important clinical 
features to ask about when assessing for the presence of LB disease in people with MCI. 
Overall, MCI-LB was associated with more severe neuropsychiatric symptoms and greater resultant 
carer distress than MCI-AD. The NPI domains which showed the greatest difference between MCI-LB 
and MCI-AD were anxiety, apathy and sleep. These findings highlight the greater symptom burden 
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experienced by people with MCI-LB and their carers in comparison to MCI-AD. As such, people with 
MCI-LB may be more likely to seek a diagnosis and may require more active clinical management 
during this phase of their disease. For patients and their carers, being able to identify the cause of 
these distressing neuropsychiatric symptoms may reduce levels of anxiety and interpersonal conflict 
related to the symptoms. The increased rate of sleep disturbance in the MCI-LB group is 
unsurprising, given the inclusion of RBD as a core diagnostic feature. However, the five 
neuropsychiatric supportive symptoms investigated (delusions, non-visual hallucinations, 
depression, anxiety and apathy) were not used to classify cases as MCI-LB or MCI-AD. 
We hypothesised that MCI-LB would be associated with worse attention/executive and visuospatial 
function, and better memory than MCI-AD. We found evidence of worse attention and visuospatial 
function in the MCI-LB group, in keeping with the cognitive profile seen in established DLB (Metzler-
Baddeley, 2007). MCI-LB cases also scored more poorly on tests of verbal fluency (both category and 
letter fluency). Verbal fluency performance is related to verbal ability and executive control (Shao et 
al., 2014). There was no difference in language function measured by the ACE-R or the Graded 
Naming Test between MCI-LB and MCI-AD, suggesting that the impairments in verbal fluency seen 
were due to greater executive dysfunction in the MCI-LB group.  
 
There was no difference between the MCI-LB and MCI-AD in tests of memory. Indeed, almost 40% of 
the MCI-LB group scored >2SD below the mean in Rey AVLT delayed recall. This is in keeping with 
previous reports of significant memory impairment in MCI-LB (Yoon et al., 2015, Kemp et al., 2017). 
This illustrates an important clinical point. Though non-amnestic MCI has a higher chance of 
converting to DLB than amnestic MCI, a substantial proportion of DLB cases will have an amnestic 
MCI in their prodromal period, which is typically multi-domain (Ferman et al., 2013). This may be 
particularly true in Memory Clinic cohorts, where amnestic problems are the usual reason for 
referral into these services. 
Three other studies have compared cognitive test scores in MCI-LB and MCI-AD (Cagnin et al., 2015, 
Yoon et al., 2015, Sadiq et al., 2017). Direct comparisons between the studies are difficult as 
different cognitive batteries have been used. The most consistent domain that differed between 
MCI-LB and MCI-AD was visuospatial function. All the studies, including this paper, also found some 
differences in executive function, though not necessarily on every executive function test. Findings 
in attention and memory domains are less consistent between the studies.  
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The heterogeneity of cognitive impairment observed in MCI-LB and MCI-AD was reflected in the 
poor discriminant ability of four cognitive tests (ACE-R fluency and visuospatial, DV mean time and 
angle task) to differentiate between MCI-LB and MCI-AD in a post-hoc analysis. Thus, though a 
pattern of prominent executive and visuospatial dysfunction is supportive of a diagnosis of MCI-LB, it 
is not sufficient to warrant a diagnosis of MCI-LB in isolation. This illustrates the supportive role of 
neuropsychological assessment in the diagnosis of MCI-LB in combination with a thorough clinical 
assessment for other features associated with Lewy body disease. 
 
Strengths and limitations 
This is the largest cohort of MCI-LB subjects published to date. All subjects had a thorough clinical 
and neuropsychological assessment. This supported accurate clinical diagnosis, which was confirmed 
by a three-rater panel. The gold standard for diagnosis will always be post-mortem brain 
examination. As MCI-LB is an evolving concept, post mortem data will take some time to emerge. 
Until then, data from well characterised clinical cohorts will be the primary source of new knowledge 
on of the prodromal stages of DLB. 
Consensus criteria for the diagnosis of MCI-LB are in development (McKeith et al., 2017). Subjects in 
this study were categorised as MCI-LB based on the presence of core clinical symptoms and 
abnormal FP-CIT SPECT imaging. The finding of a DLB pattern of cognitive impairment and associated 
neuropsychiatric symptoms in the MCI-LB group gives supporting evidence for this method of 
categorisation. FP-CIT SPECT is not yet licensed for use in MCI but has high sensitivity and specificity 
for DLB confirmed by autopsy (Thomas et al., 2017). It is reasonable to expect that the specificity 
would also be high in MCI-LB. 
Subjects were recruited to this study on the basis of suspected symptoms of Lewy body disease. 
After a thorough clinical assessment the diagnostic panel found that some participants did not have 
any core diagnostic symptoms of DLB and fulfilled criteria for MCI-AD. Rates of neuropsychiatric 
symptoms in this group were probably higher than in a non-selected MCI-AD cohort, making 
significant differences between the groups more difficult to detect. This increases the robustness of 
our findings. The somewhat atypical nature of the MCI-AD group may also explain why no 
differences were found in memory tests between MCI-LB and MCI-AD. 
The differentiation between MCI and dementia can be a difficult one to make, particularly as 
functional impairment can result from both physical and cognitive problems, and untangling the two 
can be difficult. The NIA-AA criteria were used to make a diagnosis of MCI based on the judgement 
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of the three clinicians that each participant had generally maintained “independence of function in 
daily life, with minimal aids or assistance” (Albert et al., 2011), but the cut-off in some cases may 
have been made differently by other clinicians. Due to the absence of local normal data in many of 
the cognitive tests used, it was not possible to reliably classify our cohort into single-domain/multi-
domain and amnestic/non-amnestic MCI sub-types. 
There were no significant differences between the MCI-LB and MCI-AD groups in age or years in 
education, though MCI-LB participants were more likely to be male. To account for this, gender was 
included as a covariate when analysing cognitive test scores, in addition to age and years in 
education. Several comparisons were made between MCI-LB and MCI-AD, increasing risk of Type 1 
error. A Bonferroni correction was not applied, as it would potentially obscure clinically important 
differences between the two groups. As such, these findings require replication, which we are 
currently undertaking. 
The presence or absence of neuropsychiatric symptoms was based on carer interview using the NPI. 
Symptoms in MCI-LB such as depression, anxiety and delusions were more likely to be reported in 
this context than when enquired about directly in a symptom questionnaire with both the subject 
and informant present, as previously reported in this cohort (Donaghy et al., 2017). Conversely, the 
informant was not aware of visual hallucinations in two out of twelve volunteers that reported visual 
hallucinations, as the patient had not informed them of their experiences. This illustrates the value 
of separate patient and informant interviews to investigate such symptoms both in clinical practice 
and in research studies. 
 
Conclusions 
MCI-LB, identified by the presence of core diagnostic symptoms of DLB and abnormal FP-CIT SPECT, 
is associated with neuropsychiatric symptoms and a cognitive profile similar to established DLB. This 
supports the concept of identifying MCI-LB based on the presence of core diagnostic features of DLB 
and FP-CIT SPECT imaging. 
In addition to this, the presence of two or more supportive neuropsychiatric symptoms known to be 
associated with DLB was helpful in differentiating between MCI-LB and MCI-AD, with a likelihood 
ratio of 4.2. This highlights the importance of enquiring about these symptoms in patients being 
assessed for cognitive complaints. MCI patients with these symptoms could be considered ‘at risk’ 
for later DLB, even in the absence of core symptoms of the disease.  Greater problems with 
attention, fluency and visuospatial function were observed in MCI-LB, but deficits in these domains 
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were not specific to MCI-LB due to the heterogeneity of cognitive impairment seen in both MCI 
groups. Many MCI-LB subjects also had amnestic impairment. 
Clinical evaluation to identify MCI-LB should examine neuropsychiatric symptoms associated with 
DLB such as non-visual hallucinations, delusions, anxiety, depression and apathy in addition to core 
diagnostic features. Neuropsychological profile may provide supporting evidence for a diagnosis of 
MCI-LB but is not in itself sufficient for diagnosis. 
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Tables 
Table 1. Demographic and Clinical Data 
 
MCI-AD MCI-LB  p 
n 24 41  - 
Age, mean (SD) 77.5 (8.2) 75.5 (7.6)  0.33 
Gender, n (% female) 15 (63) 14 (34)  0.03 
Years education, median (IQR) 11.5 (10.0-13.0) 10.0 (10.0-12.5)  0.50 
Informant present, n (%) 19 (79) 39 (95)  0.09 
UPDRS, mean (SD) 14.6 (7.2) 26.2 (16.2)  0.001 
NEVHI, median (IQR) 0 (0-0) 0 (0-6)  0.01 
ESS, median (IQR) 3.5 (1.0-6.8) 10 (6.5-13.5)  <0.001 
DCFS, median (IQR) 6 (4-7)  9 (6-11)  <0.001 
CAF, median (IQR) 0 (0-0) 2 (0-4)  0.002 
MSQ Q1 ‘Yes’, n (%) 3 (27) 20 (65)  0.04 
GDS, median (IQR) 1.5 (1.0-3.0) 3.0 (2.0-6.0)  0.004 
NPI Total, median (IQR) 3 (1-14) 12 (5-23)  0.003 
NPI Distress, median (IQR) 1 (0-5) 6 (2-12)  0.01 
IADL, median (IQR) 8 (7-8) 6 (5-8)  0.01 
CDR, median (IQR) 0.5 (0.5-0.5) 0.5 (0.5-0.5)  0.88 
Orthostatic  Systolic BP (mmHg), 
mean (SD) 
7.0 (19.8) -4.9 (21.6)  0.04 
Orthostatic Diastolic BP (mmHg), 
mean (SD) 
7.0 (7.7) 0.1 (10.5)  0.01 
CIRS-G, mean (SD) 9.0 (4.0) 9.1 (4.1)  0.93 
On AChI, n (%) 7 (29) 19 (46)  0.17 
On levodopa, n (%) 0 (0) 8 (20)  0.02 
UPDRS=Unified Parkinson’s Disease Rating Scale (MDS Revision); NEVHI=North East Visual Hallucinations Interview; ESS=Epworth 
Sleepiness Scale; DCFS=Dementia Cognitive Fluctuations Scale; CAF=Clinician Assessment of Fluctuation; MSQ=Mayo Sleep Questionnaire; 
GDS=Geriatric Depression Scale; NPI=Neuropsychiatric Inventory; IADL=Instrumental Activities of Daily Living; CIRS-G=Cumulative Illness 
Rating Scale for Geriatrics; AChI=Acetylcholinesterase Inhibitor. 
For informant scales (DCFS, CAF, NPI, IADL) MCI-AD n=19, MCI-LB n=39. For MSQ MCI-AD n=11, MCI-DLB n=31. For BP MCI-AD n=22, MCI-
LB n=39. 
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Table 2. Neuropsychiatric Inventory Results 
 % with each symptom NPI Severity Score   
 MCI-AD MCI-LB  MCI-AD MCI-LB   
 % % p 
 
Median 
(IQR) 
 
Median 
(IQR) 
 p 
Delusions 0 15 0.16 
 
0 (0-0) 
 
0 (0-0) 
 0.07 
Hallucinations 26 33 0.59 
 
0 (0-1) 
 
0 (0-1) 
 0.49 
Non-visual hallucinations 5 10 1    - 
Agitation/aggression 16 41 0.06 
 
0 (0-0) 
 
0 (0-2) 
 0.06 
Depression/dysphoria 37 54 0.22 
 
0 (0-1) 
 
1 (0-2) 
 0.24 
Anxiety 11 46 0.01 
 
0 (0-0) 
 
0 (0-2) 
 0.02 
Elation/euphoria 0 3 1 
 
0 (0-0) 
 
0 (0-0) 
 0.49 
Apathy/indifference 21 54 0.02 
 
0 (0-0) 
 
1 (0-4) 
 0.02 
Disinhibition 21 21 1 
 
0 (0-0) 
 
0 (0-0) 
 0.89 
Irritability/lability 21 28 0.75 
 
0 (0-0) 
 
0 (0-1) 
 0.64 
Aberrant motor behaviour 5 13 0.65 
 
0 (0-0) 
 
0 (0-0) 
 0.41 
Sleep 26 59 0.02 
 
0 (0-1) 
 
3 (0-4) 
 0.02 
Appetite/eating disorders 32 39 0.61 
 
0 (0-1) 
 
0 (0-4) 
 0.36 
MCI-AD n=19, MCI-LB n=39. Chi- squared/Fisher’s Exact tests for symptom rates, Mann-Whitney U Test for Severity Scores. 
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Table 3 Cognitive Test Scores 
 MCI-AD MCI-LB   
 Mean (SD) Mean (SD)  p 
MMSE 26.5 (2.2) 26.5 (2.0)  0.92 
ACE-R Total 79.2 (11.5) 79.3 (8.3)  0.99 
ACE-R Att./Orient. 17.0 (1.4) 16.8 (1.4)  0.84 
ACE-R Memory 15.6 (5.7) 17.4 (4.4)  0.25 
ACE-R Fluency 9.8 (2.6) 7.9 (2.8)  0.02 
ACE-R Language 22.5 (3.6) 23.6 (2.1)  0.13 
ACE-R Visuospatial 14.3 (1.9) 13.5 (2.1)  0.04 
Rey Delayed Recall 3.4 (4.3) 3.9 (3.1)  0.86 
% Rey Trial 5 Recalled 37 (39) 54 (51)  0.36 
Rey Recognition 12.1 (2.2) 11.7 (2.3)  0.88 
Failed Trails A (n (%)) 3 (13) 13 (32)  0.13 
Failed Trails B (n (%)) 11 (46) 26 (63)  0.25 
FAS 35.9 (12.9) 29.0 (14.5)  0.098 
GNT 15.8 (7.4) 17.6 (5.7)  0.26 
SRT (ms) 404 (146) 404 (155)  0.63 
SRT COV 0.31 (0.25) 0.26 (0.16)  0.96 
CRT (ms) 674 (130) 739 (247)  0.15 
CRT COV 0.23 (0.09) 0.26 (0.09)  0.13 
CRT errors 1.5 (1.7) 1.9 (1.5)  0.59 
CRT-SRT (ms) 270 (98) 333 (126)  0.07 
DV n identified 33.3 (4.6) 30.0 (6.3)  0.098 
DV time (ms) 551 (76) 584 (72)  0.04 
DV COV 0.18 (0.06) 0.20 (0.08)  0.14 
Angle Task (o) 17.6 (13.5) 26.2 (16.4)  0.001 
Motion Task 0.70 (0.28) 0.65 (0.28)  0.49 
GLM/logistic regression with age, gender and years in education as covariates. 
MMSE=Mini Mental State Examination; ACE-R=Addenbrookes Cognitive Examination Revised; Rey=Rey Auditory Verbal 
Learning Test; Trails=Trailmaking Test; GNT=Graded Naming Test; SRT=Simple Reaction Time; COV=Coefficient of Variance; 
CRT=Choice Reaction Time; DV=Digit Vigilance. 
2 subjects declined to complete Rey, 1 declined to complete DV. Computer error on SRT (n=1), CRT (n=2) and Angle (n=6). 
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